C
CapsoVision
Global medical device innovator that specializes in the fields of capsule endoscopy, medical device, and healthcare
About CapsoVision
CapsoVision, Inc. is a medical technology company specializing in capsule endoscopy systems designed to enhance diagnostic accuracy and patient comfort. The company's flagship product, CapsoCam Plus, is a capsule endoscope that captures 360-degree panoramic images of the gastrointestinal tract, providing a comprehensive view for medical professionals. CapsoVision serves healthcare providers, including hospitals and gastroenterology clinics, primarily in the United States and international markets. The company operates in the medical device industry, focusing on gastrointestinal diagnostics. CapsoVision's business model involves the sale of its CapsoCam Plus system and related software, such as CapsoView, which allows for intuitive image review and analysis. Revenue is generated through direct sales, distribution partnerships, and service agreements. The company has established strategic partnerships, such as its U.S. distribution agreement with PENTAX Medical, to expand its market reach and enhance product availability. CapsoVision's innovative approach aims to improve patient outcomes and streamline diagnostic procedures in the field of gastroenterology.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2005
- Headquarters
- Saratoga, United States
- Listing
- IPO 2025
- Employees
- 109
- Open positions
- None listed
- Dealroom signal
- 82.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Marketplace & ecommerce
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Mar 2026 | $14M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jul 2025 | $600K | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $16M | +14.9% | −$25M | -160.1% |
| 2025 | $14M | +15.3% | −$25M | -184.1% |
| 2024 | $12M | +20.5% | −$19M | -165% |
| 2023 | $9.8M | — | −$11M | -112.4% |
Growth signals
Latest recorded traffic for CapsoVision is 8.4K monthly website visits, up 211.1% over the last three months. CapsoVision's team grew 2.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Taiwanglobalangels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CapsoVision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CapsoVision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.